Log In

New? Register Here

Top Biotech & Biopharmaceutical Companies

Google has just Announced a New Health Oriented Company - Calico is a Health Company Focused on Human Health from Extending Life to Increasing Well Being. Read Full Article
Sort By:

Biogen Idec Inc.

133 Boston Post Road
WESTON, MA 02493
http://www.biogenidec.com/
  • Main Phone: (781) 464-2000
  • Fax Number: (617) 679-2617
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Elan Corporation plc ADR

Treasury Building Lower Grand Canal Street, Dubl
DUBLIN, 2
http://www.elan.com
  • Main Phone: (531) 709-4000
  • Fax Number: (531) 709-4700
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan s business focuses on neurodegenerative diseases, such as Alzheimer s disease and Parkinson s disease; autoimmune diseases, including MS and Crohn s disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn s disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Stemline Therapeutics Inc

6th Floor 750 Lexington Ave
NEW YORK, NY 10022
http://www.stemline.com
  • Main Phone: (646) 502-2310
  • Fax Number: (646) 389-0968
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Stemline Therapeutics, Inc. (Stemline) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline s StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

Cyclacel Pharmaceuticals Inc

200 Connell Drive Suite 1500
BERKELEY HEIGHTS, NJ 07922
http://www.cyclacel.com/
  • Main Phone: (908) 517-7330
  • Fax Number: (866) 271-3466
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.

NewLink Genetics Corp

Suite 5100, 2503 South Loop Drive
AMES, IA 50010
http://www.linkp.com/
  • Main Phone: (515) 296-5555
  • Fax Number: (515) 296-3520
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians. Its HyperAcute cancer immunotherapies aim to treat non-small cell lung cancer, pancreatic cancer, melanoma, prostate cancer, and breast cancer.

Alnylam Pharmaceuticals Inc.

3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
http://www.alnylam.com
  • Main Phone: (617) 551-8200
  • Fax Number: (617) 551-8101
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV), infection, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of Huntington s disease (HD).

XOMA Corp

2910 Seventh Street
BERKELEY, CA 94710
http://www.xoma.com
  • Main Phone: (510) 204-7200
  • Fax Number: (302) 655-5049
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.

Insmed Incorporated

Suite C, 9 Deer Park Drive
MONMOUTH JUNCTION, NJ 08852
http://www.insmed.com
  • Main Phone: (732) 438-9434
  • Fax Number: (804) 828-6894
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company s lead candidate ARIKACE, is engineered to deliver anti-infective directly to the site of lung infections for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). During the year ended December 31, 2011, the Company was focused on its ARIKACE clinical development program, which includes a phase II clinical study of ARIKACE in patients with NTM lung disease (TARGET-NTM), as well as a European and Canadian registration phase III clinical study of ARIKACE in CF patients with Pseudomonas lung infections (CLEAR-108). ARIKACE is considered a New Chemical Entity by the United States Food and Drug Administration (FDA), primarily due to its liposomal technology.

AbbVie Inc

1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
http://www.abbvie.com
  • Main Phone: (847) 932-7900
  • Fax Number: (302) 655-5049
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Enanta Pharmaceuticals Inc

500 Arsenal Street
WATERTOWN, MA 02472
http://www.enanta.com
  • Main Phone: (617) 607-0800
  • Fax Number: (617) 607-0530
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Announcements: None Provided


Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.